Saturday 17 October 2026
Export CRMD’s income statement to Excel — free account
CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
7.26
0.20
−2.68%
Follow CRMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
5.17 | 5.26 | 2.87 | 3.26 |
P/S ratio |
4.12 | 2.69 | 1.35 | 1.33 | |
P/FCF ratio |
11.87 | 4.85 | 2.77 | 2.46 | |
P/Operating CF |
28.62 | 8.87 | 12.74 | 7.14 | |
P/B ratio |
2.36 | 2.07 | 1.24 | 1.34 | |
Price to Tangible BV |
0.00 | 0.00 | 14.10 | 8.51 | |
EV/Sales |
4.54 | 2.68 | 1.27 | 1.09 | |
EV/EBITDA |
8.97 | 5.04 | 2.31 | 1.99 | |
EV/Operating CF |
12.97 | 4.76 | 2.56 | 1.99 | |
EV/FCF |
13.07 | 4.83 | 2.60 | 2.01 | |
Quick Ratio |
1.60 | 1.83 | 2.59 | 2.23 | |
Current Ratio |
1.94 | 2.11 | 2.98 | 2.56 | |
Net Debt/EBITDA |
1.62 | (0.06) | (0.45) | (2.09) | |
Debt/Assets |
19.32% | 17.51% | 17.76% | 16.06% | |
Debt/Equity |
0.39 | 0.36 | 0.33 | 0.32 | |
Asset Turnover |
0.52 | 0.66 | 0.83 | 0.80 | |
Operating CF/Net income |
0.28 | 6.74 | 1.10 | 3.32 | |
Capex/Depreciation |
(0.13) | (0.16) | (0.07) | (0.05) | |
Interest Coverage |
54.15 | 32.24 | — | — | |
Research and Development Expense of Revenue |
4.89% | 6.69% | 5.66% | 6.56% | |
Selling, General and Administrative Expense of Revenue |
35.13% | 30.78% | 26.88% | 27.01% | |
Intangible Assets out of Total Assets |
0.54 | 0.50 | 0.49 | 0.43 | |
Share Based Compensation of Revenue |
3.90% | 2.79% | 3.60% | 4.01% | |
Graham Net Nets |
(0.13) | (0.06) | 0.01 | 0.06 | |
Graham Number |
15.79 | 16.73 | 17.12 | 17.85 | |
Earnings Yield |
19.35% | 19.00% | 34.90% | 30.70% | |
Free Cash Flow Yield |
8.43% | 20.62% | 36.07% | 40.67% | |
Revenue per Share |
1.37 | 1.79 | 1.60 | 1.30 | |
Operating CF per Share |
0.41 | 1.31 | 0.53 | 1.10 | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.40 | 1.29 | 0.52 | 1.09 | |
Cash per Share |
0.73 | 2.06 | 2.24 | 3.27 | |
Shareholders Equity per Share |
4.93 | 5.63 | 5.50 | 5.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.93 | 5.63 | 5.50 | 5.87 | |
Free Cash Flow |
30.35 | 92.74 | 41.65 | 85.68 | |
Working Capital |
125.89 | 192.78 | 254.34 | 293.16 | |
Capital Expenditures |
(0.51) | (1.72) | (0.73) | (0.56) | |
Net Current Asset Value |
(117.20) | (53.78) | 4.53 | 37.34 | |
EV/EBIT |
9.35 | 5.55 | 2.62 | 2.32 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
8.50 | 5.58 | 2.79 | 2.84 | |
| Other line items | |||||
Average Receivables |
87.98 | 111.44 | 104.71 | 102.11 | |
Average Payables |
10.90 | 4.80 | 7.38 | 8.03 | |
Average Inventory |
17.78 | 18.66 | 19.11 | 24.11 | |
Average Assets |
414.22 | 472.49 | 482.61 | 578.33 | |
Average Common Equity |
216.42 | 244.98 | 275.97 | 340.73 |
Columns are period end dates